Page last updated: 2024-12-06

diethyl tartrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Diethyl tartrate, also known as DET, is a chiral compound with a wide range of applications in organic synthesis and industry. It is commonly used as a resolving agent for chiral compounds and as a chiral catalyst in various organic reactions. DET can be synthesized from tartaric acid through esterification with ethanol. The chirality of DET plays a significant role in its applications, as it can be used to separate enantiomers of chiral compounds and to induce stereoselectivity in reactions. Its ability to interact with chiral molecules makes it a valuable tool in the field of asymmetric synthesis, which is crucial for developing new drugs and other bioactive compounds. The unique properties of DET, including its chiral nature, high melting point, and ease of handling, contribute to its widespread use in various research and industrial settings.'

diethyl tartrate: RN given refers to R-(R*,R*)-isomer; RN for cpd without isomeric designation not avail 7/90 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID62333
CHEBI ID169338
SCHEMBL ID112148
MeSH IDM0177640

Synonyms (52)

Synonym
diethyl-d-tartrate
AKOS009031375
CHEBI:169338
diethyl 2,3-dihydroxybutanedioate
57968-71-5
racem-dimethoxysuccinic acid, dimethylester
butanedioic acid, 2,3-dihydroxy-, diethyl ester, (r*,r*)-(.+/-.)-
nsc44808
nsc8878
l-(+)-(diethyl tartrate)
diethyl 1,2-ethanedicarboxylate
ethyl tartrate
tartaric acid, diethyl ester
diethyl (2r,3r)-tartrate
nsc-8878
butanedioic acid,3-dihydroxy-, diethyl ester
ethyl tartarate
butanedioic acid,3-dihydroxy- [r-(r*,r*)]-, diethyl ester
diethyl (2r,3r)-(+)-tartrate
diethyl (+)-tartrate
diethyl tartrate
tartaric acid, (r,r)-
ethyl (+)-tartrate
diethyl (r,r)(+)tartrate
butanedioic acid, 2,3-dihydroxy-, diethyl ester, [s-(r*,r*)]-
[-]-tartaric acid diethyl ester
(+)-tartaric acid diethyl ester
racemic-dimethoxysuccinic acid, dimethyl ester
408332-88-7
c8h14o6
FT-0624780
FT-0624841
FT-0624347
SCHEMBL112148
diethyl tartarate
(+)-diethyl tartrate
1,4-diethyl 2,3-dihydroxybutanedioate
diethyl 1,2-dihydroxy-1, 2-ethanedicarboxylate
fema 2378
tartaric acid, diethyl ester (8ci)
diethyl ester(r,r)-tartaric acid
SY004617
CCG-356390
AS-11868
Q886862
diethyl dl-tartrate
STL197525
FT-0774594
DTXSID70859148
1,4-diethyl2,3-dihydroxybutanedioate
EN300-20593
Z104479048
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
3-hydroxy carboxylic acidAny hydroxy carboxylic acid which contains a hydroxy group located beta- to the carboxylic acid group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (9.09)18.2507
2000's5 (45.45)29.6817
2010's5 (45.45)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.45 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index76.57 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (52.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]